Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N(6)-adenine-specific methyltransferase METTL4 (METTL4) is an enzyme of the MT-A70 family that catalyzes N6-methylation of 2’-O-methyladenosine (Am) to form N6,2’-O-dimethyladenosine (m6Am) at internal positions of U2 small nuclear RNA (snRNA), thereby regulating RNA splicing and pre-mRNA processing[1][2][3]. METTL4 recognizes and modifies RNA substrates through a conserved catalytic DPPW motif and utilizes S-adenosylmethionine (SAM) as the methyl group donor. The enzyme is also implicated in the regulation of mitochondrial transcript levels and mitochondrial DNA (mtDNA) copy number, potentially via N6-methyladenosine modification on mtDNA, although the physiological significance and prevalence of DNA methylation activity in mammals remain under debate[3][4]. Recent evidence links METTL4-mediated mtDNA modifications to the progression of diseases such as atherosclerosis; additionally, METTL4 may play broader roles in epigenetic regulation, including repression of Polycomb target genes[3][5]. There are currently no specific inhibitors or drugs targeting METTL4 in clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N(6)-adenine-specific methyltransferase METTL4 (METTL4).